Actively Recruiting
Community Screening Study of Diabetic Retinopathy in Tianjin in 2024
Led by Li Xiaorong · Updated on 2024-07-10
18000
Participants Needed
1
Research Sites
52 weeks
Total Duration
On this page
Sponsors
L
Li Xiaorong
Lead Sponsor
T
Tianjin Medical University Eye Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
Through this study, the investigators hope to understand the prevalence and influencing factors of diabetic retinopathy in Tianjin, improve the ability of complication detection and intervention in diabetic patients in primary medical and health institutions, and build a diabetes prevention and treatment network. The investigators should adhere to the policy of prevention first, combined with prevention and control, and explore a diabetes' prevention and control model suitable for our city. Extensive publicity and education should be carried out to improve the awareness of self-management ，improve the screening rate of diabetic retinopathy, and reduce the blindness rate.
CONDITIONS
Official Title
Community Screening Study of Diabetic Retinopathy in Tianjin in 2024
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Clear awareness and ability to communicate without barriers
- Diagnosis of diabetes
You will not qualify if you...
- Have left the registered home address
- Have not lived in your current residence in the last 6 months
- Have a serious mental illness
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Tianjin Medical University Eye Hospital
Tianjin, Tianjin Municipality, China, 300000
Actively Recruiting
Research Team
J
Juping Liu, Director
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here